A colored medical neutral borosilicate glass and preparation method thereof
By introducing TiO2 and Fe2O3 as composite colorants into neutral borosilicate glass, and combining them with ZnO to adjust the network structure and using NaCl as a clarifying agent, the problem of high blue-violet light transmittance of existing glass was solved, and low-transmittance brown/black neutral borosilicate glass was prepared. This glass is suitable for pharmaceutical and cosmetic packaging and has high chemical stability and aesthetic appeal.
Patent Information
- Application Number
- CN202211069123.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-09-02
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2042-09-02
AI Technical Summary
Existing colored neutral borosilicate glass has high transmittance in the blue-violet light band and cannot effectively block light, causing photosensitive drugs and food to deteriorate during storage.
Using TiO2 and Fe2O3 as composite colorants, combined with ZnO to adjust the glass network structure, brown/black neutral borosilicate glass was prepared by a segmented temperature-controlled melting process. The colorant content was controlled to enhance the absorption capacity of blue-violet light, and NaCl was used as a clarifying agent to improve the glass quality.
The prepared brown/black neutral borosilicate glass has low transmittance in the blue-violet light band, low coefficient of thermal expansion, and excellent chemical stability. It is suitable for packaging various pharmaceuticals and cosmetics, ensuring the safety and efficacy of the drugs while also being aesthetically pleasing.
Smart Images

Figure CN115368013B_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of medical biomaterials technology, and in particular to a colored medical neutral borosilicate glass and its preparation method. Background Technology
[0002] Neutral borosilicate glass can be described as a packaging material capable of holding neutral solutions for extended periods without altering the solution's pH value. According to industry standards, it is defined as having a linear thermal expansion coefficient of less than 5 × 10⁻⁶. -7 Borosilicate glass with a temperature range of / ℃ and strong resistance to hydrolysis, acids, and alkalis. This glass can operate stably over a wide temperature range and in harsh environments, including acidic or alkaline conditions, making it an ideal packaging material for various water-soluble pharmaceuticals and foods.
[0003] Based on appearance, neutral borosilicate glass can be divided into colorless transparent glass and colored glass. Colored neutral glass can be further subdivided into gray, brown, etc. Although colorless glass is more widely used and more aesthetically pleasing, colored neutral glass must be used to prevent the deterioration of light-sensitive foods, medicines, biological agents, or chemicals (such as water-soluble vitamins, lipid drugs, nitrates, etc.) during storage. In fact, the blue-violet light band (450nm to 390nm) in the ultraviolet to visible light range has high energy and is the main culprit for the spoilage of photosensitive medicines and foods. Existing colored neutral glass technology has the problem of high blue-violet light transmittance and cannot effectively block the penetration of blue-violet light. Summary of the Invention
[0004] In view of this, the purpose of this invention is to provide a colored medical neutral borosilicate glass and a method for preparing the same. The colored medical neutral borosilicate glass of this invention can effectively block the transmission of blue-violet light.
[0005] To achieve the above-mentioned objectives, the present invention provides the following technical solution:
[0006] This invention provides a colored medical neutral borosilicate glass, made from a clarifying agent and glass raw materials, wherein the glass raw materials comprise the following components by mass percentage:
[0007] The composition comprises 70.5–74.5% SiO2, 7.5–10.5% B2O3, 5–10% Al2O3, 1.5–6.8% Na2O, 0.5–6.8% K2O, 0.2–3.4% CaO, 0.5–3.1% BaO, 0–1.0% ZnO, 0–1.5% Fe2O3, and 0–3.1% TiO2, wherein the mass percentages of ZnO, Fe2O3, and TiO2 are all not 0.
[0008] The clarifying agent is NaCl, and the mass fraction of NaCl is 0.5% to 2% of the glass raw material.
[0009] Preferably, the glass raw material for the colored medical neutral borosilicate glass comprises the following components by mass percentage:
[0010] 71.5–73% SiO2, 7.5–10.5% B2O3, 6–8% Al2O3, 5–6.8% Na2O, 0.5–6.8% K2O, 0.4–1% CaO, 2.1–2.7% BaO, 0.5–1.0% ZnO, 0.4–1.2% Fe2O3 and 1–3.1% TiO2;
[0011] The mass fraction of NaCl is 1 to 1.5% of the glass raw material.
[0012] Preferably, the glass raw material for the colored medical neutral borosilicate glass comprises the following components in varying amounts:
[0013] SiO2: 71.8wt%, B2O3: 9.5wt%, Al2O3: 6.0wt%, Na2O: 6.8wt%, K2O: 0.5wt%, CaO: 0.5wt%, BaO: 2.1wt%, ZnO: 1.0wt%, Fe2O3: 0.8wt%, TiO2: 1.0wt%;
[0014] The mass fraction of NaCl is 1.5% of the glass raw material.
[0015] Preferably, the glass raw material for the colored medical neutral borosilicate glass comprises the following components in varying amounts:
[0016] SiO2: 72wt%, B2O3: 9.5wt%, Al2O3: 5.3wt%, Na2O: 6.4wt%, K2O: 0.5wt%, CaO: 0.4wt%, BaO: 2.1wt%, ZnO: 0.5wt%, Fe2O3: 0.6wt%, TiO2: 2.7wt%;
[0017] The mass fraction of NaCl is 1.5% of the glass raw material.
[0018] Preferably, the glass raw material for the colored medical neutral borosilicate glass comprises the following components in varying amounts:
[0019] SiO2: 72wt%, B2O3: 9.5wt%, Al2O3: 5.3wt%, Na2O: 6.4wt%, K2O: 0.5wt%, CaO: 0.4wt%, BaO: 2.1wt%, ZnO: 0.5wt%, Fe2O3: 1.2wt%, TiO2: 2.1wt%;
[0020] The mass fraction of NaCl is 1.5% of the glass raw material.
[0021] Preferably, the glass raw material for the colored medical neutral borosilicate glass comprises the following components in varying amounts:
[0022] SiO2: 71.8wt%, B2O3: 9.5wt%, Al2O3: 5.3wt%, Na2O: 6.4wt%, K2O: 0.5wt%, CaO: 0.4wt%, BaO: 2.1wt%, ZnO: 0.5wt%, Fe2O3: 0.4wt%, TiO2: 3.1wt%;
[0023] The mass fraction of NaCl is 1.5% of the glass raw material.
[0024] This invention also provides a method for preparing the colored medical neutral borosilicate glass described in the above technical solution, comprising the following steps:
[0025] The glass raw material and the clarifying agent are mixed and then melted to obtain a glass melt;
[0026] The glass molten material is sequentially subjected to casting, first cooling, annealing, and second cooling to obtain the colored medical neutral borosilicate glass.
[0027] Preferably, the melting process is carried out in the range of 25 to 700°C with a heating rate of 3 to 4°C / min; in the range of 700 to 1200°C with a heating rate of 4 to 5°C / min; and in the range of 1200 to 1650°C with a heating rate of 5 to 10°C / min, and the temperature is maintained for 1.5 to 2.5 hours.
[0028] Preferably, the cooling rate of the first cooling is 700-800°C / min.
[0029] Preferably, the annealing treatment is performed at a temperature of 580–600°C for 2–3 hours.
[0030] This invention provides a colored medical neutral borosilicate glass, prepared from a clarifying agent and glass raw materials. The glass raw materials comprise the following components by mass percentage: 70.5–74.5% SiO2, 7.5–10.5% B2O3, 5–10% Al2O3, 1.5–6.8% Na2O, 0.5–6.8% K2O, 0.2–3.4% CaO, 0.5–3.1% BaO, 0–1.0% ZnO, 0–1.5% Fe2O3, and 0–3.1% TiO2, wherein the mass percentages of ZnO, Fe2O3, and TiO2 are all not zero. The clarifying agent is NaCl, and the mass fraction of NaCl is 0.5–2% of the glass raw materials.
[0031] In this invention, transition metal oxides (Fe2O3 and TiO2) have good compatibility with glass, are easy to color, and are relatively stable at high temperatures. As glass colorants, this invention introduces TiO2 and Fe2O3 as composite colorants into neutral borosilicate glass. Both colorants are non-toxic and harmless, and their introduction amount is controlled. Ti 4+ It can absorb the blue-violet portion of visible light, and when added alone, it gives glass a pale brownish-yellow appearance. The coloring of Fe₂O₃ is related to its valence state. 2+ It will make the glass turn pale blue, while Fe 3+ This process imparts a brown (tea) color to the glass and enables the formation of absorption peaks in the ultraviolet and infrared bands of the spectrum. Introducing small amounts of both into a neutral glass system results in a final brown / black glass with strong absorption of blue-violet light. Furthermore, adjusting the relative content of both within a range of 0 to 100% allows for color variations from tea-colored to dark brown. Small amounts of TiO2 and Fe2O3 act as network modifiers in neutral borosilicate glass, which can degrade the basic properties of the glass to some extent; therefore, their usage must be strictly limited. To mitigate the negative impact of both on chemical stability, this invention uses a small amount of ZnO instead of CaO. ZnO participates in the formation of the borosilicate glass network in the form of [ZnO4], increasing network integrity and improving resistance to selective leaching from various solutions.
[0032] Data from the examples show that, after water resistance testing of the prepared brown neutral borosilicate glass according to relevant standards, it was found that Ti... 4+ and Fe 3+The tendency for precipitation is extremely small, and it does not reduce water resistance. As a packaging material, it has no potential health or safety impact. Furthermore, because neutral borosilicate glass requires a very high melting temperature, some Fe2O3 will be reduced to Fe3O4, releasing oxygen. Since oxygen diffuses slowly in molten borosilicate glass, an appropriate amount of NaCl is introduced to enhance the clarification effect of the glass melt. NaCl completely volatilizes during the melting stage, therefore it is not considered a glass component in this invention; its usage in the raw materials is given as an additive.
[0033] Compared with the prior art, the beneficial technical effects of the present invention include:
[0034] (1) The brown / black neutral borosilicate glass of this invention has a low coefficient of thermal expansion (20-300℃) and excellent chemical stability, and can be used as packaging material for various injectable solutions, biological products, frozen preparations and high-end cosmetics. The water resistance of this invention, determined by the 98℃ particle water resistance test, reaches HGB1 level, which is a neutral borosilicate glass that meets international standards.
[0035] (2) This invention uses a small amount of TiO2 and Fe2O3 as composite colorants to prepare brown / black glass with very low transmittance in the blue-violet light band. TiO2 and Fe2O3, as modifiers, provide free oxygen, which converts [AlO6] and [BO3] into [AlO4] and [BO4] respectively, thereby enhancing network connectivity, reducing the amplitude of thermal vibration of particles inside the glass, and improving thermal stability. While meeting the main performance requirements of ordinary pharmaceutical packaging materials, this invention can also serve as a container for photosensitive drugs and chemicals, more effectively ensuring the efficacy and safety of drugs and chemicals. At the same time, this invention retains its transparent characteristics, making it more aesthetically pleasing.
[0036] This invention also provides a method for preparing the colored medical neutral borosilicate glass described in the above-mentioned technical solution. This invention designs a unique segmented temperature control heating system based on the chemical reaction rules between raw materials during glass melting, reducing boron volatilization. B2O3 can increase the connectivity of the glass network structure and improve the main properties of the glass; however, its melting temperature is much lower than that of SiO2, which may lead to excessive volatilization during melting. A stepped variable-speed heating method is adopted to ensure that B2O3 fully combines with alkali metal oxide components before volatilization. B2O3 combines with Na2O before 700℃ to form various borates, such as sodium tetraborate. Slow heating during this stage reduces boron loss at high temperatures. This invention has low preparation costs, low environmental impact, and is conducive to large-scale industrial production. Attached Figure Description
[0037] Figure 1The images shown are actual pictures of the colored medical neutral borosilicate glass prepared in Examples 1 to 4 of the present invention, wherein (1) is Example 1, (2) is Example 2, (3) is Example 3, and (4) is Example 4;
[0038] Figure 2 The image shows the ultraviolet-visible transmittance of the brown neutral glass prepared in Examples 1-4 of this invention. Detailed Implementation
[0039] This invention provides a colored medical neutral borosilicate glass, made from a clarifying agent and glass raw materials, wherein the glass raw materials comprise the following components by mass percentage:
[0040] The composition comprises 70.5–74.5% SiO2, 7.5–10.5% B2O3, 5–10% Al2O3, 1.5–6.8% Na2O, 0.5–6.8% K2O, 0.2–3.4% CaO, 0.5–3.1% BaO, 0–1.0% ZnO, 0–1.5% Fe2O3, and 0–3.1% TiO2, wherein the mass percentages of ZnO, Fe2O3, and TiO2 are all not 0.
[0041] The clarifying agent is NaCl, and the mass fraction of NaCl is 0.5% to 2% of the glass raw material.
[0042] In this invention, the colored medical neutral borosilicate glass is preferably brown or black.
[0043] In this invention, the glass raw material preferably comprises the following components by mass percentage:
[0044] 71.5–73% SiO2, 7.5–10.5% B2O3, 6–8% Al2O3, 5–6.8% Na2O, 0.5–6.8% K2O, 0.4–1% CaO, 2.1–2.7% BaO, 0.5–1.0% ZnO, 0.4–1.2% Fe2O3 and 1–3.1% TiO2;
[0045] The mass fraction of NaCl is preferably 1 to 1.5% of the glass raw material, more preferably 1.5%.
[0046] In a specific embodiment of the present invention, the glass raw material preferably comprises the following components in the following amounts:
[0047] SiO2: 71.8wt%, B2O3: 9.5wt%, Al2O3: 6.0wt%, Na2O: 6.8wt%, K2O: 0.5wt%, CaO: 0.5wt%, BaO: 2.1wt%, ZnO: 1.0wt%, Fe2O3: 0.8wt%, TiO2: 1.0wt%;
[0048] Or may include the following components:
[0049] SiO2: 72wt%, B2O3: 9.5wt%, Al2O3: 5.3wt%, Na2O: 6.4wt%, K2O: 0.5wt%, CaO: 0.4wt%, BaO: 2.1wt%, ZnO: 0.5wt%, Fe2O3: 0.6wt%, TiO2: 2.7wt%;
[0050] Or may include the following components:
[0051] SiO2: 72wt%, B2O3: 9.5wt%, Al2O3: 5.3wt%, Na2O: 6.4wt%, K2O: 0.5wt%, CaO: 0.4wt%, BaO: 2.1wt%, ZnO: 0.5wt%, Fe2O3: 1.2wt%, TiO2: 2.1wt%;
[0052] Or may include the following components:
[0053] SiO2: 71.8wt%, B2O3: 9.5wt%, Al2O3: 5.3wt%, Na2O: 6.4wt%, K2O: 0.5wt%, CaO: 0.4wt%, BaO: 2.1wt%, ZnO: 0.5wt%, Fe2O3: 0.4wt%, TiO2: 3.1wt%.
[0054] This invention also provides a method for preparing the colored medical neutral borosilicate glass described in the above technical solution, comprising the following steps:
[0055] The glass raw material and the clarifying agent are mixed and then melted to obtain a glass melt;
[0056] The glass molten material is sequentially subjected to casting, first cooling, annealing, and second cooling to obtain the colored medical neutral borosilicate glass.
[0057] The present invention involves mixing and melting the glass raw material and the clarifying agent to obtain a glass melt.
[0058] In this invention, the melting is preferably carried out in an air atmosphere.
[0059] In this invention, the melting process is preferably carried out in the range of 25–700°C with a heating rate of 3–4°C / min; in the range of 700–1200°C with a heating rate of 4–5°C / min; and in the range of 1200–1650°C with a heating rate of 5–10°C / min, followed by a holding time of 1.5–2.5 h. This invention employs a segmented temperature control heating system, which to some extent improves the problem of boron volatilization and ensures the main properties of neutral borosilicate glass. Boron can increase the thermal and chemical stability of glass, but boron compounds generally have low melting points and are prone to excessive volatilization at high temperatures, negatively impacting glass properties. This invention, through strict temperature control, promotes the incorporation of boron as a network form into the glass under a fixed boron doping level.
[0060] After obtaining the glass melt, the present invention sequentially performs casting, first cooling, annealing and second cooling on the glass melt to obtain the colored medical neutral borosilicate glass.
[0061] The present invention does not impose any special limitation on the specific method of casting; any method known to those skilled in the art can be used.
[0062] In this invention, the cooling rate of the first cooling is preferably 700-800°C / min.
[0063] In this invention, the annealing temperature is preferably 580-600°C, more preferably 590°C, and the annealing time is preferably 2-3 hours.
[0064] In this invention, the second cooling is preferably furnace-borne cooling.
[0065] The present invention does not have any special limitations on the application of the colored medical neutral borosilicate glass, and any application method known to those skilled in the art can be used.
[0066] To further illustrate the present invention, the following detailed description, in conjunction with examples, of the colored medical neutral borosilicate glass and its preparation method provided by the present invention, should not be construed as limiting the scope of protection of the present invention.
[0067] Example 1
[0068] The raw materials for brown medical neutral borosilicate glass have the following mass percentages: SiO2: 71.8wt%, B2O3: 9.5wt%, Al2O3: 6.0wt%, Na2O: 6.8wt%, K2O: 0.5wt%, CaO: 0.5wt%, BaO: 2.1wt%, ZnO: 1.0wt%, Fe2O3: 0.8wt%, TiO2: 1.0wt%; clarifying agent NaCl (calculated separately): 1.5wt%. The glass is heated to a melting temperature of 1650℃ in air at a heating rate of 3℃ / min at 25–700℃, 4℃ / min at 700–1200℃, and 5℃ / min at 1200–1650℃, held for 2 hours, then rapidly cooled to 580℃ at 800℃ / min and held for 2 hours for annealing. Finally, it is furnace cooled to room temperature.
[0069] Example 2
[0070] The mass percentage of the raw materials for brown medical neutral borosilicate glass is as follows: SiO2: 72wt%, B2O3: 9.5wt%, Al2O3: 5.3wt%, Na2O: 6.4wt%, K2O: 0.5wt%, CaO: 0.4wt%, BaO: 2.1wt%, ZnO: 0.5wt%, Fe2O3: 0.6wt%, TiO2: 2.7wt%, and clarifying agent NaCl (calculated separately): 1.5wt%. The glass is heated to a melting temperature of 1650℃ in air at a heating rate of 4℃ / min at 25–700℃; 5℃ / min at 700–1200℃; and 10℃ / min at 1200–1650℃, held for 2 hours, then rapidly cooled to 580℃ at 700℃ / min and held for 2 hours for annealing. Finally, it is furnace cooled to room temperature.
[0071] Example 3
[0072] The mass percentage of the glass raw materials for black medical neutral borosilicate glass is as follows: SiO2: 72wt%, B2O3: 9.5wt%, Al2O3: 5.3wt%, Na2O: 6.4wt%, K2O: 0.5wt%, CaO: 0.4wt%, BaO: 2.1wt%, ZnO: 0.5wt%, Fe2O3: 1.2wt%, TiO2: 2.1wt%, and clarifying agent NaCl (calculated separately): 1.5wt%. The glass is heated to a melting temperature of 1650℃ in air at a heating rate of 4℃ / min at 25–700℃; at 4℃ / min at 700–1200℃; and at 10℃ / min at 1200–1650℃, held for 2 hours, then rapidly cooled to 580℃ at 800℃ / min and held for 2 hours for annealing. Finally, it is furnace cooled to room temperature.
[0073] Example 4
[0074] The mass percentage of the raw materials for brown medical neutral borosilicate glass is as follows: SiO2: 71.8wt%, B2O3: 9.5wt%, Al2O3: 5.3wt%, Na2O: 6.4wt%, K2O: 0.5wt%, CaO: 0.4wt%, BaO: 2.1wt%, ZnO: 0.5wt%, Fe2O3: 0.4wt%, TiO2: 3.1wt%, and clarifying agent NaCl (calculated separately): 1.5wt%. The glass is heated to a melting temperature of 1650℃ in air at a heating rate of 4℃ / min at 25–700℃; 4℃ / min at 700–1200℃; and 10℃ / min at 1200–1650℃, held for 3 hours, then rapidly cooled to 580℃ at 800℃ / min and held for 2 hours for annealing. Finally, it is furnace cooled to room temperature.
[0075] Figure 1 The images shown are actual pictures of the neutral borosilicate glasses prepared in Examples 1-4, where (1) is Example 1, (2) is Example 2, (3) is Example 3, and (4) is Example 4. Figure 1 As can be seen, the neutral borosilicate glasses prepared in Examples 1, 2, 3, and 4 are all brown / black transparent and homogeneous, and no visible bubbles are present.
[0076] Comparative Example 1
[0077] A method for preparing neutral glass is as follows:
[0078] The mass percentages of the brown borosilicate glass components are as follows: SiO2: 65.0%, B2O3: 9.8%, Al2O3: 6.0%, Na2O: 6.6%, K2O: 3.0%, Li2O: 0.8%, MnO2: 1.8%, Fe2O3: 1.0%, TiO2: 2.0%, with the remainder being CeO2. The raw materials are mixed according to the above proportions, heated to 1600℃ in an air atmosphere, held for 4 hours, rapidly cooled to 600℃, held for 2 hours for annealing, and then cooled to room temperature in the furnace.
[0079] Comparative Example 2
[0080] A method for preparing borosilicate glass is as follows:
[0081] The mass percentages of the brown borosilicate glass components are as follows: SiO2: 68.0%, B2O3: 10.0%, Al2O3: 6.2%, Na2O: 7.0%, K2O: 3.0%, Li2O: 0.7%, MnO2: 3.5%, Fe2O3: 1.5%, TiO2: 2.5%, with the remainder being CeO2. The raw materials are mixed according to the above proportions, heated to the melting temperature of 1600℃ in an air atmosphere, held for 3 hours, rapidly cooled to 600℃, held for 2 hours for annealing, and then cooled to room temperature in the furnace.
[0082] The main performance testing methods are as follows:
[0083] The average linear thermal expansion coefficient of the strip glass sample was tested according to the "YBB00202003-2015 Method for Determination of Average Linear Thermal Expansion Coefficient".
[0084] The acid resistance of glass blocks was tested according to the "YBB00342004-2015 Test Method for Resistance to Boiling Hydrochloric Acid Immersion of Glass".
[0085] The resistance of glass blocks to alkali corrosion was tested in accordance with ISO 696-1991 Test method and classification of glass against boiling mixed alkaline solutions.
[0086] The alkali leaching amount of the glass particles was tested in accordance with ISO 719-1985 Test method and classification of water resistance of glass particles at 98°C.
[0087] The glasses prepared in Examples 1-4 were processed into thin sheets with a thickness of 2 mm, and their transmittance in the wavelength range of 200 to 800 nm was measured using a UV-Vis spectrophotometer. The results are as follows. Figure 2 .
[0088] Although Comparative Examples 1 and 2 simultaneously introduce Fe₂O₃ and TiO₂, they also simultaneously introduce MnO₂ and CeO₂ as colorants. This results in a high total content of colorants in Comparative Examples 1 and 2, and a lack of means to counteract their negative effects, inevitably leading to deterioration in thermal properties and chemical stability. Furthermore, the decomposition of these colorants at high temperatures generates more oxygen, a problem not considered in Comparative Examples 1 and 2. Therefore, the formulation design of the embodiments of the present invention is more reasonable.
[0089] The test results are shown in Table 1. It can be seen that the neutral borosilicate glass obtained in Examples 1-4 of this invention meets the relevant standards for medical glass in terms of thermal stability, acid resistance, alkali resistance, and water resistance. It is a qualified medical neutral borosilicate glass, specifically: acid resistance grade 1, alkali resistance grade A2, water resistance grade HGB1, and a linear thermal expansion coefficient of less than 5 × 10⁻⁶. -7 / ℃. The linear thermal expansion coefficient of the embodiments of the present invention is lower, and the resistance to thermal stress is stronger, thus having a wider allowable temperature range.
[0090] Combination Figure 1 The displayed images show that Examples 1-4 are all transparent or semi-transparent in appearance, and colored brown / black. From... Figure 2 The transmittance data shows that, compared to colorless glass, brown / black glass has an average transmittance of less than 15% in the 450nm to 390nm wavelength range, with the lowest approaching 0%, which is better than comparative examples 1-2. It can more effectively filter out blue-violet light and ultraviolet light, making it suitable for packaging materials of ordinary pharmaceuticals and photosensitive drugs. Furthermore, by changing the relative contents of TiO2 and Fe2O3 while maintaining the total colorant content at less than 3.5wt%, the appearance can be varied from light brown to dark brown.
[0091] Table 1. Performance test results of the glasses prepared in Examples 1-4 and Comparative Examples 1-2
[0092]
[0093] Comparing the chemical composition of the formulations, Examples 1-4 of this invention contain fewer colorants. Since these colorant oxides are all network exosomes, they are detrimental to improving the basic properties of the glass, and their increased content also means an increased possibility of leaching, which could potentially affect the performance of the pharmaceutical product and the health of the user. According to the results of inductively coupled plasma atomic emission spectrometry (ICP-AES), the total leaching amount of colorant ions in the glass prepared according to the formulations and processes described in Examples 1-4 of this invention is less than 0.01 mg / L, and there are no toxic or harmful negative effects. Therefore, compared with Comparative Examples 1-2, the design of this invention is more reasonable.
[0094] In Examples 1-4 of this invention, a small amount of clarifying agent is added. Considering production costs, carbonates are typically used as raw materials for glass, but this increases the probability of bubbles appearing in the product. This invention uses the clarifying agent NaCl to ensure glass quality, achieving a better clarifying effect without increasing the clarifying temperature or extending the holding time.
[0095] The above description is merely a preferred embodiment of the present invention and is not intended to limit the present invention in any way. It should be noted that those skilled in the art can make various improvements and modifications without departing from the principles of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.
Claims
1. A method for preparing colored medical neutral borosilicate glass, characterized in that: The following steps are involved: Mixing glass raw materials and a clarifier and then melting them to obtain a glass melt; The glass melt is sequentially cast, first cooled, annealed and second cooled to obtain the colored medical neutral borosilicate glass; The glass raw materials specifically include the following components: SiO2: 72wt%, B2O3: 9.5wt%, Al2O3: 5.3wt%, Na2O: 6.4wt%, K2O: 0.5wt%, CaO: 0.4wt%, BaO: 2.1wt%, ZnO: 0.5wt%, Fe2O3: 1.2wt%, TiO2: 2.1wt%; The clarifier is NaCl; the mass fraction of NaCl is 1.5% of the glass raw material; The melting process is as follows: in the range of 25-700°C, the heating rate is 3-4°C / min; in the range of 700-1200°C, the heating rate is 4-5°C / min; in the range of 1200-1650°C, the heating rate is 5-10°C / min, and the temperature is kept for 1.5-2.5h; The cooling rate of the first cooling is 700-800° C. / min.
2. The preparation method according to claim 1, characterized in that: The annealing treatment is carried out at a temperature of 580 to 600° C. and for a time of 2 to 3 hours.
